Introduction {#s1}
============

Gallbladder cancer is a rare malignancy with an incidence of 1.13/100,000 ([@B1]). This fatal disease has a high mortality rate ([@B2]), resulting in an overall 5-year survival rate of \<5% ([@B3]). Gallbladder adenocarcinoma (GBA) is the most common subtype of gallbladder cancer, accounting for \~76--90% ([@B4], [@B5]). The National Comprehensive Cancer Network (NCCN) clinical guidelines recommend simple cholecystectomy (SC) to be adequate for the treatment of T1a (mucosal involvement) GBA since it is a regional disease ([@B6]). However, for T1b (muscular involvement) and more advanced GBA, extended cholecystectomy (EC), including lymph node (LN) dissection, should be considered ([@B6]--[@B9]). Remarkably, some reports have found no clinical benefit to T1b GBA patients receiving EC vs. SC ([@B10]--[@B13]). The need for LN dissection in T1b GBA patients remains controversial; therefore, a well-defined tumor index that considers LN metastasis in T1b GBA is urgently needed.

As part of the American Joint Committee on Cancer (AJCC) tumor-lymph-metastasis (TNM) staging system, the T category of hollow viscera tumors (e.g., stomach, intestines, and gallbladder) describes vertical tumor penetration; the effect of horizontal tumor extent (tumor size) is not considered. Gotoda et al. ([@B14]) reported a strong association between tumor size larger than 3 cm and LN metastasis in early gastric cancer. In colorectal cancer, tumors exceeding 4.5 cm were also found to be associated with high N classification ([@B15]). The relationship between tumor size and LN metastasis in gallbladder cancer, to our best knowledge, has not yet been elucidated. This study was performed to evaluate the relationship between tumor size and LN metastasis in T1b GBA to provide more optimal treatment.

Materials and Methods {#s2}
=====================

Ethics Statement
----------------

This study was approved by the institutional review board of Shanghai Tenth People\'s Hospital, Tongji University School of Medicine. Patients from the Surveillance, Epidemiology, and End Results (SEER) database had previously consented to participate in any scientific research worldwide.

Patients
--------

T1b GBA was defined as an adenocarcinoma confined to the muscular layer of gallbladder. All patients with T1b GBA were collected from the SEER database, the largest publicly available cancer dataset in the United States ([@B16]). Information related to T1b GBA at diagnosis was available for patient data registered between 2004 and 2015. Only patients enrolled after 2004 were collected because depth of tumor invasion was not recorded before 2004 in the SEER database. All T1b patients were uniformly staged according to the 6th or 8th edition of the American Joint Committee on Cancer (AJCC) staging manual because both share the same definition of T1b category ([@B17], [@B18]). Patients with distant metastasis (stage IV) were not eligible because surgical treatment was not the standard therapy. Detailed selection and exclusion criteria are shown in [Figure 1](#F1){ref-type="fig"}.

![Patient selection flowchart.](fonc-09-00409-g0001){#F1}

Statistical Analysis
--------------------

Absolute number and incidence of T1b GBA were calculated according to tumor size, age, grading, gender, race/ethnicity, marital status, and status of LNs. The number of patients with positive LNs was the frequency of T1b GBA patients diagnosed with positive LNs. Race/ethnicity representation among our study cohort included those patients identified as White, Black, and Other race/ethnicity. Tumors were staged according to the guidelines outlined in the 8th edition of the AJCC staging manual. Kaplan--Meier survival curves were generated to analyze overall survival (OS) and statistical significance was considered to be two-sided *P* \< 0.05.

Results {#s3}
=======

Patient Characteristics
-----------------------

In total, clinical data from 277 patients in the SEER database with pathologically diagnosed T1b GBA were included in this study ([Table 1](#T1){ref-type="table"}). The median age at diagnosis was 69 years (range, 37--95 years). The proportion of females (71.5%) was higher than males (28.5%). Race-adjusted GBA incidence was 66.4% within the white ethnicity, followed by other (Asian or Pacific Islander, American Indian/Alaska Native, and unknown race/ethnicity) (17.0%) and Black (16.6%).

###### 

Demographic and tumor characteristics of GBA patients from the SEER database (*n* = 277).

  **Characteristics**                                           **No.(%)**
  ------------------------------------------------------------- ------------
  **MEAN TUMOR SIZE (range, mm)**                               26.7(1-80)
  **GRADING[^\*^](#TN1){ref-type="table-fn"}**                  
       I+II                                                     220(79.4%)
       III+IV                                                   48(17.3%)
  **MEDIAN AGE (range, years)**                                 69(37--95)
  **GENDER**                                                    
       Male                                                     79(28.5%)
       Female                                                   198(71.5%)
  **ETHNICITY**                                                 
       White                                                    184(66.4%)
       Black                                                    46(16.6%)
       Other                                                    47(17.0%)
  **MARITAL STATUS**                                            
       Married                                                  146(52.7%)
       Single/Widowed/Divorced/Separated                        115(41.5%)
       Other                                                    16(5.8%)
  **STATUS OF LNs**                                             
       negative(stage IA[^\*\*^](#TN2){ref-type="table-fn"})    262(94.6%)
       positive(stage IIB[^\*\*^](#TN2){ref-type="table-fn"})   15(5.4%)
  **LYMPHADENECTOMY**                                           
       No                                                       150(54.2%)
       Yes                                                      127(45.8%)
       Mean No. of evaluated LNs if Yes(range)                  3.9(1-80)

*9 cases missing*.

*According to the 6th AJCC TNM staging system*.

Association Between LN Metastasis and Tumor Size
------------------------------------------------

Of the 277 patients with T1b GBA, 127 (45.8%) underwent EC, while 150 (54.2%) patients underwent SC. Additionally, among the 127 patients receiving EC ([Table 2](#T2){ref-type="table"}), 23 (18.1%) patients had tumors \<1.0 cm in diameter, none of which had positive LNs. Three (11.1%) patients had positive LNs in the group of tumors ≥ 1.0 cm and \< 2.0 cm in diameter; six (23.1%) had positive LNs in the group of tumors ≥2.0 cm and \<3.0 cm in diameter; two (10.5%) had positive LNs in the group of tumors ≥ 3.0 cm and \< 4.0 cm in diameter; three (23.1%) had positive LNs in the group of tumors ≥ 4.0 cm and 5.0 cm in diameter; one (16.7%) had positive LNs in the group of tumors ≥5.0 cm and \<6.0 cm in diameter; none had positive LNs in group of tumors ≥6.0 cm in diameter probably due to the small sample. Thus, patients with tumors \<1.0 cm and those with tumors ≥1.0 cm and \<6.0 cm were compared with Fisher\'s Exact Test and it was found that the latter had a higher rate of LN metastasis ([Figure 2](#F2){ref-type="fig"}, *P* = 0.038).

###### 

Proportion of patients with positive LNs at each tumor size interval.

  **Patients with lymphadenectomy**      **SEER (*****n*** **=** **127)**                                                                                   
  -------------------------------------- ---------------------------------- ----------- ----------- ------------ ------------ ----------- ------- --------- ------------
  Tumor size(mm)                         1-9                                10-19       20-29       30-39        40-49        50-59       60-69   70-79     80-160
  No. of total patients                  23                                 27          26          19           13           6           3       4         6
  No. of patients with positive LNs(%)   0                                  3 (11.1%)   6 (23.1%)   2 (10.5%)    3 (23.1%)    1 (16.7%)   0       0         0
  Mean no. of evaluated LNs (Range)      4.2 (1-26)                         2.6 (1-7)   3.7 (1-8)   6.7 (1-80)   3.2 (1-12)   3.2 (1-6)   1 (1)   2 (1-5)   5.8 (1-17)

![Comparison of GBA patients receiving EC according to LN status and tumor size.](fonc-09-00409-g0002){#F2}

Survival Analysis
-----------------

OS of T1b GBA patients receiving SC or EC are presented in [Figure 3](#F3){ref-type="fig"}. Compared with SC treatment, EC did not prolong the OS of T1b GBA patients with tumor size \< 1 cm (*P* = 0.694). Clinical benefit was observed in T1b GBA patients with tumor size ≥1 cm receiving EC vs. those receiving SC (*P* = 0.012).

![OS of GBA patients stratified by tumor size and surgical treatment using Kaplan-Meier analysis. **(A)** Tumor size \<1 cm; **(B)** Tumor size ≥1 cm.](fonc-09-00409-g0003){#F3}

Discussion {#s4}
==========

The present study evaluated the number of positive LNs in patients with T1b GBA and the relationship between tumor size and LN metastasis. There were no positive LNs observed in T1b GBA with tumors \<1 cm in diameter. These results indicate that SC is adequate for the treatment of T1b GBA in patients with a tumor \<1 cm in diameter. Treatment distinction based on tumor size will minimize thdiameter. These results indicate that SC is adequate for the treatment of T1b GBA in patientse need for reoperation from complications in T1b GBA patients and further extend criteria for local treatment.

LN metastasis is the most common metastatic modality in gallbladder cancer. The rate of such metastasis can be as high as 60--80% in stage T3 or T4 gallbladder cancer ([@B19]). LN metastasis is notably infrequent in early gallbladder cancer, however. Kohei Shibata et al. published a retrospective study of 72 patients who underwent macroscopically curative surgical resection for stage T1b--T3 gallbladder cancer, and none of the patients with T1b disease had lymphatic invasion ([@B20]). Further, Shirai et al. reported that LN metastasis was rarely found in T1b gallbladder cancer ([@B21]). In our population-based study, 5.4% (15/277) of patients with T1b GBA had LN metastasis, but no LN metastasis was observed in patients with T1b GBA \< 1 cm in diameter. Similarly, for T1b GBA patients with tumor \<1 cm in diameter, significant survival differences were not observed between patients receiving SC and those receiving EC. These findings indicated that patients with T1b GBA \< 1 cm in diameter were a population with specific indolent tumor behavior.

Most studies support the NCCN guideline recommendation that EC be performed for T1b GBA ([@B6]--[@B9]), while other studies have argued SC to be adequate ([@B10]--[@B13]). We speculate that the controversy may be elucidated by the proportion of T1b GBA \<1 cm in diameter to entire T1b GBA cohort. When the proportion is low, there is a significant difference observed between T1b GBA patients receiving SC and those receiving EC. Conversely, when the proportion is high enough, there is no significant difference observed. However, for the treatment of T1b GBA ≥1 cm in diameter, EC is still recommended to improve clinical outcomes.

Although we used the one of the largest cancer patient databases in an attempt to evaluate the relationship between LN metastasis and tumor size, the present findings were limited by its retrospective nature. The sample size of this study is relatively small and more large-scale studies with prospective data are needed to validate these conclusions.
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